Your session is about to expire
← Back to Search
Transcranial Direct Current Stimulation
tDCS for Enhancing Speech Motor Learning in Healthy Subjects
N/A
Recruiting
Led By Adam Buchwald, PhD
Research Sponsored by New York University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2 days after training
Summary
This trial will study whether electric stimulation of speech and non-speech regions can improve speech motor learning and help treat speech impairments.
Who is the study for?
This trial is for native English speakers who learned the language from birth at home and have not been exposed to certain languages with specific consonant clusters. Participants must pass a hearing test and have no history of speech, language, or hearing disorders. They should also not have any tDCS risk factors like skin damage where the device attaches, implants that react to electricity or magnets, or metal in their body.
What is being tested?
The study tests how different types of electrical brain stimulation affect learning new speech sounds. Healthy adults will practice nonwords while receiving one of six treatments: positive or negative stimulation over speech motor areas, positive or negative stimulation over frontal regions, negative stimulation over non-speech motor areas (positive already done), or sham (fake) treatment.
What are the potential side effects?
tDCS can cause mild side effects such as itching, tingling, headache during application; fatigue after sessions; nausea; and discomfort on scalp under electrode placement. Serious side effects are rare but may include seizures and mood changes.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 2 days after training
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2 days after training
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in percentage of accurately produced words from baseline to retention
Secondary study objectives
Change in duration from first consonant to second consonant from baseline to retention
Trial Design
5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Anodal speech motor tDCS (Anode: C5; Cathode: Fp2)Experimental Treatment1 Intervention
Speech motor learning task performed with the stimulation condition in the arm title.
Group II: Cathodal speech motor tDCS (Anode: Fp2; Cathode: C5)Active Control1 Intervention
Speech motor learning task performed with the stimulation condition in the arm title.
Group III: Anodal IFG tDCS (Anode: F3; Cathode: Fp2)Active Control1 Intervention
Speech motor learning task performed with the stimulation condition in the arm title.
Group IV: Cathodal IFG tDCS (Cathode: F3; Anode: Fp2)Active Control1 Intervention
Speech motor learning task performed with the stimulation condition in the arm title.
Group V: Sham tDCSPlacebo Group1 Intervention
Speech motor learning task performed with the stimulation condition in the arm title.
Find a Location
Who is running the clinical trial?
New York UniversityLead Sponsor
242 Previous Clinical Trials
220,065 Total Patients Enrolled
Adam Buchwald, PhDPrincipal InvestigatorNew York University